By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel is bearish on Alumis, citing high valuation, binary event risk, and cash runway concerns. They agree that the upcoming lupus Phase 2b data is crucial but consider it high-risk due to historical failure rates in autoimmune trials.
Risk: Failure of the upcoming lupus Phase 2b trial and potential dilution from future funding rounds.
Opportunity: A successful lupus trial could attract a buyout, potentially at a premium, due to the 'Sotyktu' halo effect.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
ACT Capital Management acquired 174,250 ALMS shares in the first quarter, with an estimated trade value of $4.36 million based on average first-quarter pricing.
The quarter-end position value was $3.84 million, reflecting the value of the newly established position.
The transaction represented a 3.42% change relative to ACT Capital Management’s 13F reportable assets.
On May 8, 2026, ACT Capital Management disclosed a new position in Alumis (NASDAQ:ALMS), acquiring 174,250 shares in a trade estimated at $4.36 million based on quarterly average pricing.
According to a Securities and Exchange Commission (SEC) filing dated May 8, 2026, ACT Capital Management opened a new position in Alumis by purchasing 174,250 shares. The estimated value of this acquisition is $4.36 million, based on the average unadjusted closing price during the quarter. The quarter-end valuation of the position stood at $3.84 million, reflecting both share count and market price changes.
NASDAQ:TGTX: $8.27 million (6.5% of AUM)
As of May 7, 2026, Alumis shares were priced at $23.76, up a staggering 350% over the past year and vastly outperforming the S&P 500’s roughly 30% gain in the same period.
| Metric | Value | |---|---| | Market capitalization | $3 billion | | Revenue (TTM) | $24.05 million | | Net income (TTM) | ($243.32 million) |
Alumis is a clinical-stage biotechnology company specializing in the development of innovative therapies for autoimmune and neuroinflammatory diseases. The company leverages allosteric TYK2 inhibition technology to address unmet medical needs in chronic immune disorders. With a focused pipeline and a strategy centered on differentiated drug candidates, Alumis aims to establish a competitive position in the biopharmaceutical sector.
Alumis shares have already surged roughly 350% over the past year, but ACT Capital still initiated a position that immediately became more than 3% of assets under management. That suggests conviction around upcoming drug catalysts and the broader commercial potential of the company’s TYK2 pipeline.
In March, Alumis reported positive Phase 3 data for envudeucitinib in moderate-to-severe plaque psoriasis, with roughly 65% of patients achieving PASI 90 skin clearance and more than 40% achieving PASI 100 at Week 24. The company plans to submit an NDA in the second half of 2026 and expects potentially pivotal Phase 2b lupus data in the third quarter.
Alumis also strengthened its balance sheet in January with a $345 million stock offering and finished 2025 with $308.5 million in cash and marketable securities, which coincided with a massive stock surge.
For long-term investors, the opportunity here is obvious, but so is the risk. Alumis has promising data and multiple near-term catalysts, though the company still posted a $243 million net loss last year as research spending accelerated. Upcoming results will ultimately determine the stock’s trajectory.
Before you buy stock in Alumis, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Alumis wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $471,827! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,319,291!
Now, it’s worth noting Stock Advisor’s total average return is 986% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 10, 2026. *
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Chevron and Krystal Biotech. The Motley Fool recommends TG Therapeutics. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"The current valuation reflects a 'best-case' clinical scenario, leaving zero margin of safety for the upcoming Phase 2b lupus readout."
The 350% run-up in ALMS makes an entry here look like a 'chase' rather than a value play. While ACT Capital’s 3% allocation signals institutional conviction in the TYK2 inhibitor pipeline, the market is already pricing in near-perfect clinical outcomes. With a $3 billion market cap and $243 million in annual losses, Alumis is trading on pure binary event risk. The upcoming Phase 2b lupus data in Q3 is the real make-or-break; if the efficacy isn't superior to existing JAK inhibitors or the current TYK2 leader, Sotyktu, the valuation will face a brutal correction. Investors are betting on a buyout, not just commercial success.
If Alumis successfully differentiates its TYK2 profile with superior safety or efficacy, it becomes an immediate, high-margin M&A target for Big Pharma players desperate to replenish autoimmune pipelines.
"ALMS's $3B valuation embeds flawless execution in a competitive TYK2 field led by BMS's established Sotyktu, overlooking clinical/regulatory risks and cash burn."
ACT Capital's $4M ALMS stake is just 3% of AUM in a portfolio heavy on energy (CVX, XOM) and select biotechs (KRYS, CELC, TGTX), signaling modest conviction after a 350% YTD surge to $3B mcap. Positive Ph3 psoriasis data for envudeucitinib (65% PASI90) sets up H2 2026 NDA, but TYK2 space is crowded—BMS's Sotyktu (deucravacitinib) is approved, commercializing, and capturing share. $243M TTM losses on $24M rev highlight burn rate risks despite $308M cash + $345M raise. Lupus Ph2b Q3 is high-risk binary in a field with prior TYK2 failures.
If lupus Ph2b hits and psoriasis NDA sails through, ALMS could dominate with superior efficacy profiles, justifying the premium as a pipeline leader in autoimmune megamarkets worth $100B+.
"A $4M buy by a small fund in a stock already up 350% signals late-stage momentum-chasing, not informed conviction—especially when the company's only near-term catalyst (lupus Phase 2b) carries typical biotech failure risk and the approved-drug competitive set is already crowded."
ACT Capital's $4.36M ALMS buy is being framed as conviction-driven, but the timing is suspicious: stock up 350% YTD, position immediately underwater 12% by quarter-end, and the fund is a $127M AUM shop making a 3%+ bet on a clinical-stage biotech with $243M annual losses and no approved drugs. The positive Phase 3 psoriasis data (65% PASI 90) is real, but psoriasis is a crowded market with multiple approved TYK2 inhibitors already. Lupus Phase 2b data in Q3 2026 is the actual catalyst—but lupus trials fail frequently, and the stock's 350% run may have already priced in optimism. The article conflates a single fund's purchase with validation; it doesn't.
If envudeucitinib's efficacy profile materially exceeds competitors (Opzelura, Sotyktu) in head-to-head trials or lupus data is unexpectedly strong, the stock could re-rate higher despite current valuation. ACT may simply be early-stage biotech specialists who see something the market hasn't.
"ACT’s ALMS bet is a binary, catalyst-driven wager that currently seems priced for optimistic outcomes rather than sustainable value."
ACT Capital’s new Alumis (ALMS) stake signals some institutional curiosity, but the read is likely overstated as a breakthrough bet. The position (~174k shares, ~$4.36m) ends at ~$3.84m, suggesting tactical, not core conviction. Alumis is clinical-stage with a heavy burn and a $3B market cap despite only $24m in TTM revenue and a $243m net loss; the stock’s ~350% run over the past year looks more like sector momentum than durable cash flow. The article cites positive Phase 3 data and an H2 2026 NDA, plus near-term lupus data, but those outcomes are binary and could be delayed or fail, and dilution from a March offering muddies the odds of meaningful upside.
Even if the data is real, a 3% AUM stake in a one-asset biotech with high failure risk offers limited durable upside; binary outcomes and dilution could erase gains.
"The market is underestimating the value of Alumis as a defensive M&A target for Big Pharma, regardless of its current clinical-stage burn rate."
Claude, your skepticism regarding the fund's size is valid, but you're missing the regulatory arbitrage. ACT Capital isn't betting on commercial success; they are betting on the 'BMS-Sotyktu' halo effect. The market is ignoring the potential for a 'fast-follow' acquisition. If Alumis shows even marginal differentiation in safety, Big Pharma will pay a premium to avoid the commercial execution risk of building a TYK2 franchise from scratch. This isn't about revenue; it's about defensive IP consolidation.
"Alumis' limited cash runway amplifies binary lupus risk, undermining near-term acquisition appeal."
Gemini, your M&A halo effect downplays cash runway fragility: $308M cash + $345M raise = ~$650M against $243M annual losses yields just 2.5-3yr runway. Lupus Ph2b Q3 demands flawless execution in a 70-80% failure-prone space (historical autoimmune Phase 2 rates); psoriasis alone won't lure buyers at $3B mcap when Sotyktu dominates with proven sales.
"Dilution risk from future funding rounds is the real valuation killer, not cash runway alone."
Grok's runway math is tight but overlooks a critical detail: $345M raise was March 2024; cash burn accelerates post-Phase 3 readout (regulatory, manufacturing scale-up). The 2.5-3yr runway assumes flat spend. More pressing: nobody's addressed dilution. If ALMS needs another raise pre-NDA, current shareholders face 30-40% haircut. That erodes the M&A premium Gemini's betting on. Sotyktu's commercial traction actually strengthens ACT's exit thesis—BMS might acquire to consolidate, not compete.
"Even strong lupus data may be overshadowed by dilution and pre-NDA fundraising that erodes upside, undermining any supposed M&A premium."
Claude's dilution warning matters, but I’d push it further: even with strong lupus data, the immediate risk is another funding round that could wipe out upside before an NDA, especially if time-to-NDA slides. The 3B+ valuation already sits on a binary event, and a pre-NDA raise would halve or worse existing holders’ stake while potential buyers demand more certainty on safety signals than the psoriasis data suggests. This is not just a runway issue—it's capital structure risk.
The panel is bearish on Alumis, citing high valuation, binary event risk, and cash runway concerns. They agree that the upcoming lupus Phase 2b data is crucial but consider it high-risk due to historical failure rates in autoimmune trials.
A successful lupus trial could attract a buyout, potentially at a premium, due to the 'Sotyktu' halo effect.
Failure of the upcoming lupus Phase 2b trial and potential dilution from future funding rounds.